Article Metrics


Online attention

A7.08 Novel agents for blocking the interaction of immune complexes with the activatory FCγRIIIA receptor

DOI: 10.1136/annrheumdis-2016-209124.139 DOI Help

Authors: E. W Baxter (University of Leeds) , J. I Robinson (University of Leeds) , D. C Tomlinson (University of Leeds) , R. J Foster (University of Leeds) , R. L Owen (Diamond Light Source) , S. J Win (University of Leeds) , J. E Nettleship (Oxford Protein Production Facility-UK) , C Tiede (University of Leeds) , J Kankanala (University of Leeds) , R. J Owens (University of Oxford) , C. W. G Fishwick (University of Leeds) , M. J Mcpherson (University of Leeds) , A. W Morgan (University of Leeds)
Co-authored by industrial partner: No

Type: Journal Paper
Journal: Annals Of The Rheumatic Diseases , VOL 75 , PAGES A58 - A59

State: Published (Approved)
Published: February 2016

Abstract: Protein-protein interactions are essential for the control of cellular functions and critical for regulation of the immune system. One example is the binding of Fc regions of Immunoglobulin G to their receptors (Fcγ Receptors). High sequence identity (98%) between the genes encoding FcγRIIIa and FcγRIIIb has led to the lack of specific agents against this important therapeutic target. We aimed to develop a novel drug development pipeline using artificial binding proteins called Adhirons both for the identification of novel therapeutics and to guide drug discovery through the identification of novel hot spots/ druggable surfaces on the receptor.

Journal Keywords: Immunology; Epidemiology

Subject Areas: Biology and Bio-materials, Chemistry

Technical Areas: